WO2006110037A2 - Preparation of 2-substituted 4-chl0r0-5-f0rmylimidaz0les by vilsmeier reaction of the condensation product of glycine and an imido ester with a formamide in the presence of a triflate (trifluormethanξsulphonate) catalyst - Google Patents

Preparation of 2-substituted 4-chl0r0-5-f0rmylimidaz0les by vilsmeier reaction of the condensation product of glycine and an imido ester with a formamide in the presence of a triflate (trifluormethanξsulphonate) catalyst Download PDF

Info

Publication number
WO2006110037A2
WO2006110037A2 PCT/NL2006/050077 NL2006050077W WO2006110037A2 WO 2006110037 A2 WO2006110037 A2 WO 2006110037A2 NL 2006050077 W NL2006050077 W NL 2006050077W WO 2006110037 A2 WO2006110037 A2 WO 2006110037A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
formylimidazole
chloro
formula
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2006/050077
Other languages
French (fr)
Other versions
WO2006110037A3 (en
Inventor
Janmejay Rajnikant Vyas
Venkata Satya Varma Nidadavolu
Anand Prakash Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dishman Carbogen Amcis Ltd
Pluim Henk
Original Assignee
Dishman Pharmaceuticals and Chemicals Ltd
Pluim Henk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dishman Pharmaceuticals and Chemicals Ltd, Pluim Henk filed Critical Dishman Pharmaceuticals and Chemicals Ltd
Priority to DE602006017675T priority Critical patent/DE602006017675D1/en
Priority to US11/911,659 priority patent/US20080200690A1/en
Priority to EP06733056A priority patent/EP1871745B1/en
Priority to JP2008506390A priority patent/JP2008535911A/en
Priority to AT06733056T priority patent/ATE485278T1/en
Publication of WO2006110037A2 publication Critical patent/WO2006110037A2/en
Publication of WO2006110037A3 publication Critical patent/WO2006110037A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Definitions

  • the invention relates to a process of producing formylimidazoles, in particular a new process for the preparation of 2-substituted 5-formylimidazoles, in particular 2-butyl-5- formylimidazole.
  • the invention also relates to an improved process for the preparation of 2-substituted 4-chloro-5-formylimidazoles, especially 2-butyl-4-chloro-5- formy limidazo Ie .
  • Formylimidazoles are important intermediates for pharmaceutical active ingredients, for example diuretics and antihypertensive agents.
  • reaction pressure can be reduced to an acceptable level of 3 bar (at 70 0 C) in the presence of 10 equivalents of ammonia if the proper solvent is chosen, for instance from diisopropyl ether, toluene and methanol.
  • Methanol showed to be particularly suitable, resulting in 2-butyl-4- hydroxymethylimidazole with 79 % yield, attributed to the great solubility of NH 3 in methanol.
  • the second step then involves the oxidation of the hydroxymethylimidazole to the corresponding formy limidazo Ie.
  • the oxidation of a hydroxymethylimidazole can be performed with a reagent containing a heavy metal, e.g. manganese dioxide or nitric acid, but more beneficially, with a noble metal catalyst such as platinum-bismuth, platinum black, platinum or palladium on activated carbon, while passing in oxygen.
  • a noble metal catalyst such as platinum-bismuth, platinum black, platinum or palladium on activated carbon, while passing in oxygen.
  • the noble metal catalyst can be used in combination with hydrogen peroxide according to US 6,040,457.
  • the invention relates to process for the preparation of a 2-substituted 4-chloro-5- formylimidazole of the formula:
  • R is hydrogen, alkyl, alkenyl, cycloalkyl, arylalkyl or aryl, wherein glycine is reacted with an imido ester of the formula:
  • R 2 and R 3 are identical or different and each is a (Ci - C 4 ) alkyl, wherein said Vilsmeier reaction is performed in the presence of a triflate catalyst.
  • An alkyl group is taken to mean a straight-chain or branched (Ci-Ce)-alkyl group, in particular methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl and its isomers, or hexyl and its isomers.
  • a preferred alkyl group for R is the n-butyl group.
  • a preferred alkyl group for Ri is a (Ci-C 4 )-alkyl group, particularly preferably methyl.
  • alkenyl group is taken to mean a straight-chain or branched (Ci-Ce)-alkenyl group, in particular 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, pentenyl and its isomers, or hexenyl and its isomers.
  • a preferred alkenyl group is 2-butenyl or 3- butenyl.
  • Cycloalkyl is expediently taken to mean cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • An arylalkyl group expediently has the meaning phenyl-(Ci-C 6 )-alkyl, preferably benzyl.
  • Aryl correspondingly has the preferred meaning of phenyl.
  • the aryl group can have one or more substituents, such as, (Ci-C4)-alkyl, alkoxy, halo, nitro or amino, on its aromatic nucleus.
  • halo expediently includes chlorine, bromine or iodine, preferably chlorine.
  • the reaction of the imido ester with glycine is preferably performed at a pH between 4 and 12, and at a temperature between - 20 and 80 0 C.
  • the glycine is customarily present suspended in a suitable solvent, such as an aliphatic alcohol such as methanol or ethanol, optionally mixed with water.
  • a suitable solvent such as an aliphatic alcohol such as methanol or ethanol, optionally mixed with water.
  • the imido ester can be added in the form of a solution in an inert solvent, such as toluene, chlorobenzene, or an aliphatic alcohol such as methanol.
  • the reaction partners in the first stage are preferably used stoichiometrically.
  • the resulting compound of the general formula III can be isolated from the reaction mixture in a manner known to those skilled in the art, but preferably is not isolated and instead is further reacted directly in the Vilsmeier reaction.
  • the Vilsmeier reagent comprises a chlorinating agent, preferably selected from the group consisting of phosphorus oxychloride, thionyl chloride, phosgene or phosgene-releasing compounds, phosphorus trichloride or phosphorus pentachloride.
  • a preferred chlorinating agent is phosphorus oxychloride.
  • the Vilsmeier reagent further comprises a formamide of the general formula IV. Expediently the molar ratio of chlorinating agent to formamide is between 1 to 1 and 4 to 1.
  • the preferred formamide is N,N-dimethylformamide.
  • the Vilsmeier reagent is preferably used in excess, serving as a solvent at the same time. However, it is also possible to add an inert solvent such as toluene, chlorobenzene or xylene.
  • the reaction temperature for the Vilsmeier reaction is preferably between 60 and 200 0 C.
  • the Vilsmeier reaction is performed in the presence of a triflate catalyst, more formally known as a trifiuoromethanesulfonate catalyst.
  • a triflate catalyst more formally known as a trifiuoromethanesulfonate catalyst.
  • Other perfiuoroalkanesulfonate catalyst can also be used. It is preferably a lanthanide(III) or group IV metal trifiuoromethanesulfonate, more preferably the metal cation is copper(II), cerium(IV) or lanthanum(III).
  • the catalyst is preferably present in an amount between 0.1 and 10 wt% based on glycine, more preferably between 0.2 and 8 wt%, most preferably between 0.5 and 5 wt%, based on the weight of glycine.
  • the final product is a 2-substituted 4-chloro-5-formylimidazole. It is preferably 2-butyl-4-chloro-5-formylimidazole (BCFI), obtained from reacting glycine with methyl pentanimidate, wherein (pentanimidoylamino)acetic acid is the intermediate compound converted in the Vilsmeier reaction.
  • BCFI 2-butyl-4-chloro-5-formylimidazole
  • the 2-substituted 4-chloro-5- formylimidazole is typically produced by the process according to the invention with a yield of about 70 - 75 %, based on glycine, and with a purity of more than 99 %, preferably even more than 99.5 % as determined by HPLC.
  • 4-chloro-5-formylimidazole wherein said imido ester of formula (II) is prepared by reacting a nitrile having formula R-C ⁇ N, preferably valeronitrile, with methanol in the presence of hydrochloric acid gas, followed by a treatment with ammonia.
  • This reaction is preferably performed at a temperature between -20 and 10 0 C, and HCl gas is blown through the reaction temperature for a time between 5 - 24 hours. It is preferred to add another amount of methanol afterwards, and bring the reaction mixture in a methanolic ammonia solution at a pH between 7 and 11, while the temperature is preferably maintained at 0 - 50 0 C. The reaction is completed within 10 hours.
  • the precipitated salts are removed by filtration and washed with an aliphatic alcohol, preferably methanol, and the filtrate could be concentrated in a manner known to those skilled in the art.
  • the imido ester is preferably not isolated and instead is further reacted directly with glycine.
  • a 2-substituted 5-formylimidazole sometimes also referred to as 2-substituted imidazole-4-carbaldehyde
  • 2-substituted imidazole-4-carbaldehyde can conveniently be prepared from the corresponding 4-chloro-5-formylimidazole by applying a hydrodehalogenation step. Yields are observed higher than 50 %, based on glycine, far better than if prepared from the hydroxymethylimidazole as taught in the art. This is surprising, given the fact that this new method of producing 2-substituted 5- formylimidazole involves a more elaborate synthesis route, including an additional step of dechlorination.
  • the method has the advantage that it can be performed as a one-pot synthesis, starting from simple and inexpensive compounds such as valeronitrile and glycine.
  • the invention thus also relates to a process for the production of a 2-substituted 5-formylimidazole of the formula:
  • R is hydrogen, alkyl, alkenyl, cycloalkyl, arylalkyl or aryl, by subjecting the corresponding 2-substituted 4-chloro-5-formylimidazole to hydrodehalogenation in the presence of a noble metal catalyst.
  • the preferred 2-substituted 5-formylimidazole is 2-butyl 5-formylimidazole, prepared from 2-butyl-4-chloro-5-formylimidazole.
  • Hydrodehalogenation is performed in the presence of a catalyst comprising a noble metal (including the metallic form as well as the form of a salt, oxide or the like) selected from the group consisting of platinum, palladium and gold.
  • a noble metal including the metallic form as well as the form of a salt, oxide or the like
  • platinum and palladium are suited for practical use, most preferably palladium.
  • These noble metals may be used in combination with bismuth, cerium, lead, indium or the like as a second component.
  • the noble metal catalyst is used as such or, when necessary, in the form supported on a carrier such as active carbon, silica or alumina.
  • the noble metal catalyst is preferably palladium on carbon, palladium being present in an amount between 5 and 15 wt%, based on the weight of 2-butyl-4-chloro-5-formylimidazole
  • the hydrodehalogenation is preferably preformed in the presence of an aliphatic alcohol such as methanol, and triethylamine, preferably in an amount of 1 - 20 wt%, more preferably 5 - 15 wt%, based on the total reaction mixture, and a 2 - 10 kg, even more preferably 4 - 5 kg hydrogen pressure, and at a preferred temperature of 0 - 50 0 C, more preferably 15 - 30 0 C.
  • the noble metal catalyst is preferably present in an amount of 0.1 - 2 wt%, more preferably 0.5 - 1 wt%.
  • the 2-substituted 5-formylimidazole is produced from a 2-substituted 4-chloro-5-formylimidazole that is produced by the process according to the invention, i.e. wherein the Vilsmeier reaction is performed in the presence of a triflate catalyst.
  • the 2-substituted 5-formylimidazole is produced from R-C ⁇ N, wherein R has the meaning cited above, according to the aforementioned process. It is thus possible to produce 2-substituted 5-formylimidazole without any intermediate isolation and purification steps according to an advantageous one-pot synthesis route, thereby reaching yields of more than 50 %, based on glycine, and a purity of more than 98 %, as determined by HPLC.
  • Example 1 Preparation of methyl pentanimidate from valeronitrile 100 g (1.20 mol) valeronitrile was charged in 58 ml of methanol and cooled to -5 to -10 0 C. HCl gas was slowly passed through the solution for 15-18 hrs. Nitrogen pressure of 1.5 to 2.0 kg /cm 2 was applied for 14 hrs at 0 - 15 0 C, followed by the addition of 55 ml methanol and stirring for another 60 min.
  • reaction mass was then transferred to a methanolic ammonia solution (12-15 wt%) and stirred for 3 hrs at 20 - 30 0 C, while maintaining the pH at 8 - 9.
  • Precipitated material was then filtered and washed with 25 ml of methanol. The filtrate was concentrated until complete removal of methanol by distillation under reduced pressure
  • reaction mixture was cooled to 50 - 55 0 C, followed by filtration to remove the platinum on carbon.
  • the filtered catalyst was washed with 25 ml of deionised water.
  • the remaining reaction mixture was cooled to 10 - 15 0 C and the pH adjusted to 7.5 - 8.0 using 50% sulfuric acid, and stirred for another 3 hrs before filtering and washing with 2 x 50 ml of chilled deionised water (10 0 C).
  • Example 2 Preparation of BCFI from methyl pentanimidate using a triflate catalyst 50 g (0.666 mol) of glycine was added to freshly prepared methanolic sodium hydroxide solution (sodium hydroxide 26.64 g (0.666 mol) in 250 ml of methanol) at O 0 C and stirred for another 15 min. 80 g (0.70 mol) of the methyl pentanimidate prepared according to example 1 was added over a period of 10 - 15 min to the above suspension at 0 - 5 0 C and stirring was continued for 16 hrs at room temperature. The solvent was then distilled under vacuum below 5O 0 C.
  • the mixture was taken from the autoclave and the solvent was removed under reduced pressure below 50 0 C.
  • 250 ml of deionised water was added to the dried mixture and it was cooled to 25-30 0 C.
  • the pH was adjusted to 1.2 using diluted hydrochloric acid.
  • the aqueous layer was then washed with 50 ml of dichloromethane to remove traces of the starting material.
  • the pH was then readjusted to 6.8 - 7.5 using a sodium carbonate solution, and the aqueous layer was extracted with 3 x 150 ml of dichloromethane. Afterwards, the dichloromethane was dried with sodium sulfate for 30 min and then filtered to remove the sodium sulfate.
  • reaction mass was transferred to a methanolic ammonia solution (12 - 15 wt% and stirred for 3 hrs at 20 - 30 0 C, while keeping the pH at 8.0 - 9.0.
  • Precipitated material was filtered off and washed with 15 ml of methanol.
  • the filtrate was concentrated by distillation under reduced pressure (650 - 700 mm Hg) at a temperature not exceeding 90 0 C, followed by cooling to give pentanimidate.
  • 50 g (0.666 mol) of glycine was added to a freshly prepared methanolic sodium hydroxide solution (sodium hydroxide 26.64 g (0.666 mol) in 250 ml of methanol) at
  • the mixture was unloaded from the autoclave.
  • the solvent was removed under reduced pressure, thereby keeping the temperature below 50 0 C.
  • 250 ml of deionised water was added and it was cooled to 25 - 30 0 C.
  • the pH was adjusted to 1.2 with diluted hydrochloric acid and the aqueous layer was extracted with 60 ml of dichloromethane to remove traces of the starting material.
  • the pH was then readjusted to 6.8 - 7.5 using sodium carbonate solution, and the aqueous layer was extracted with 3 x 160 ml of dichloromethane.
  • the dichloromethane solution was dried with sodium sulfate for 30 min and the sodium sulfate removed by filtering.
  • the filtrate was evaporated to dryness, 300 ml of hexane was added at 45 0 C, and the mixture was cooled to 10 - 15 0 C and maintained at that temperature for another 30 min, to obtain 2- butyl-5 - formy limidazo Ie .
  • the product was isolated by filtration followed by washing with 150 ml of chilled hexane (10 0 C) and dried at 55 - 60 0 C for 6 hrs, with a yield of 58 g. Analysis of the product by HPLC showed 99.0 % purity. The yield was about 55 % on the basis of valeronitrile.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to process for the preparation of a 2-substituted 4-chloro-5-formylimidazole of the formula (I), in which R is hydrogen, alkyl, alkenyl, cycloalkyl, arylalkyl or aryl, wherein glycine is reacted with an imido ester of the formula (II), in which R has the meaning recited above, and R1 is alkyl, to give a compound of the formula (III), which is then subjected to a Vilsmeier reaction using a chlorinating agent and a formamide of the formula (IV), in which R8 and R3 are identical or different and each is a (C1-C4) alkyl, wherein said Vilsmeier reaction is performed in the presence of a triflate catalyst.

Description

Preparation of 2-substituted 4-chloro-5-formylimidazole and 5-formylimidazole
FIELD OF THE INVENTION
The invention relates to a process of producing formylimidazoles, in particular a new process for the preparation of 2-substituted 5-formylimidazoles, in particular 2-butyl-5- formylimidazole. The invention also relates to an improved process for the preparation of 2-substituted 4-chloro-5-formylimidazoles, especially 2-butyl-4-chloro-5- formy limidazo Ie .
BACKGROUND OF THE INVENTION
Formylimidazoles are important intermediates for pharmaceutical active ingredients, for example diuretics and antihypertensive agents.
In the art 2-substituted 5-formylimidazoles are produced on a commercial scale via a 2-substituted 4-hydroxymethylimidazole intermediate. According to Y. -J. Shi et al. "A practical synthesis of 2-butyl-4(5)-chloro-5(4)-hydroxymethyl-lH-imidazole", Synthetic Communications 23 (1993) p. 2623 - 2630, the intermediate 2-butyl-4- hydroxymethylimidazole can be prepared by reacting methyl pentanimidate with 1,3- dihydroxyacetone at elevated reaction temperature and at high NH3 pressure. Although extremely high pressures of about 28 bar are reported, the reaction pressure can be reduced to an acceptable level of 3 bar (at 70 0C) in the presence of 10 equivalents of ammonia if the proper solvent is chosen, for instance from diisopropyl ether, toluene and methanol. Methanol showed to be particularly suitable, resulting in 2-butyl-4- hydroxymethylimidazole with 79 % yield, attributed to the great solubility of NH3 in methanol.
The second step then involves the oxidation of the hydroxymethylimidazole to the corresponding formy limidazo Ie. According to US 5,336,779 the oxidation of a hydroxymethylimidazole can be performed with a reagent containing a heavy metal, e.g. manganese dioxide or nitric acid, but more beneficially, with a noble metal catalyst such as platinum-bismuth, platinum black, platinum or palladium on activated carbon, while passing in oxygen. Alternatively, the noble metal catalyst can be used in combination with hydrogen peroxide according to US 6,040,457.
However, the synthesis of formylimidazoles via hydroxymethylimidazole does not comply with the requirements of a large-scale industrial process, because of the necessity of high pressure to establish imidazole ring closure in the first step. Moreover, although Y. -J. Shi et al. report acceptable yields of about 71 % for chloro-5- formylimidazole prepared from the hydroxymethylimidazole intermediate, 2- substituted 5-formylimidazole is obtained from the same intermediate through oxidation with less than 40 % yield. This is probably related to overoxidation of the intermediate compound.
For these reasons inexpensive alternative synthesis routes are searched, therewith avoiding the need for 2-substituted 5 -hydroxymethylimidazole compounds. For 2- substituted 5-chloroformylimidazole this has resulted in the synthesis route taught in US 5,696,272, wherein glycine is reacted with an imido ester such as methyl pentanimidate, and the intermediate compound thus obtained is then converted to a 2- substituted 5-chloroformylimidazole by a Vilsmeier reagent which is composed of a chlorinating agent and a formamide. Both steps are conveniently performed in a one- pot synthesis, without the need to isolate the intermediate compound before subsequent ring closure and chlorination. P. Ambalavanan et al. "Crystal structures of two imidazole derivatives" MoI.
Cryst. Liq. Cryst. vol. 393 (2003) 75 - 82 describes the synthesis of 2-n-butyl-5-chloro- 3H-imidazole-4-carbaldehyde (BCIC) from glycine and methyl pentanimidate using POCl3. A 55% yield is reported. Similarly, A. Davood et al. "Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4(5)-chloro-2-methyl- 5(4)-imidazolyl substituent" Bollettino Chimico Farmaceutico vol. 140, no. 6 (2001) 381-386 teaches the synthesis of 4(5)-chloro-2-methylimidazole-5 (4)-carboxaldehyde from glycine using POCI3 with a success rate of 14 %.
Unfortunately, despite all efforts to produce 2-substituted 5- chloro formylimidazoles more economically, yields and purity still stay behind in comparison to the high-pressure process according to J. Shi et al.. For 2-butyl 5- chloroformylimidazole a yield of 62 %, based on glycine, and a purity of about 85 % were reported in example 4 of US 5,696,272. Others report even lower yields. DESCRIPTION OF THE INVENTION
It is an object of the invention to provide 2-substituted 4-chloro-5-formylimidazoles in higher yields and with high purity levels compared to methods existing in the art, and to simplify the synthesis route leading to these compounds.
It has been found that the yield of the production of 2-substituted 4-chloro-5- formylimidazoles, sometimes also referred to as 2-substituted 5-chloroimidazole-4- carbaldehydes, can be increased with another 15 % to over 70 %, based on glycine, by performing the Vilsmeier reaction in the synthesis route according to US 5,696,272 in the presence of a trifiate catalyst. The use of such a catalyst also enhances the purity of the final product to more than 99.5 %, comparable to a commercial-grade compound, far better than achieved in the art. The high purity is realised without any additional recrystallisation steps.
The invention relates to process for the preparation of a 2-substituted 4-chloro-5- formylimidazole of the formula:
Figure imgf000004_0001
in which R is hydrogen, alkyl, alkenyl, cycloalkyl, arylalkyl or aryl, wherein glycine is reacted with an imido ester of the formula:
Figure imgf000004_0002
in which R has the meaning recited above, and Ri is alkyl, to give a compound of the formula:
Figure imgf000004_0003
III, which is then subjected to a Vilsmeier reaction using a chlorinating agent and a formamide of the formula:
Figure imgf000005_0001
in which R2 and R3 are identical or different and each is a (Ci - C4) alkyl, wherein said Vilsmeier reaction is performed in the presence of a triflate catalyst.
In formulae I, II, III and IV, the general substituents R, R1, R2 and R3 have the following meanings:
An alkyl group is taken to mean a straight-chain or branched (Ci-Ce)-alkyl group, in particular methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl and its isomers, or hexyl and its isomers. A preferred alkyl group for R is the n-butyl group. A preferred alkyl group for Ri is a (Ci-C4)-alkyl group, particularly preferably methyl.
An alkenyl group is taken to mean a straight-chain or branched (Ci-Ce)-alkenyl group, in particular 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, pentenyl and its isomers, or hexenyl and its isomers. A preferred alkenyl group is 2-butenyl or 3- butenyl.
Cycloalkyl is expediently taken to mean cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
An arylalkyl group expediently has the meaning phenyl-(Ci-C6)-alkyl, preferably benzyl. Aryl correspondingly has the preferred meaning of phenyl. The aryl group can have one or more substituents, such as, (Ci-C4)-alkyl, alkoxy, halo, nitro or amino, on its aromatic nucleus.
The term halo expediently includes chlorine, bromine or iodine, preferably chlorine.
It is to be noted that tautomers, in particular 5-chloro-4-formylimidazoles and analogues are also encompassed by the above description.
The reaction of the imido ester with glycine is preferably performed at a pH between 4 and 12, and at a temperature between - 20 and 80 0C. The glycine is customarily present suspended in a suitable solvent, such as an aliphatic alcohol such as methanol or ethanol, optionally mixed with water. The imido ester can be added in the form of a solution in an inert solvent, such as toluene, chlorobenzene, or an aliphatic alcohol such as methanol. The reaction partners in the first stage are preferably used stoichiometrically. After a reaction time expediently of 2 hours to 48 hours, the resulting compound of the general formula III can be isolated from the reaction mixture in a manner known to those skilled in the art, but preferably is not isolated and instead is further reacted directly in the Vilsmeier reaction.
The Vilsmeier reagent comprises a chlorinating agent, preferably selected from the group consisting of phosphorus oxychloride, thionyl chloride, phosgene or phosgene-releasing compounds, phosphorus trichloride or phosphorus pentachloride. A preferred chlorinating agent is phosphorus oxychloride.
The Vilsmeier reagent further comprises a formamide of the general formula IV. Expediently the molar ratio of chlorinating agent to formamide is between 1 to 1 and 4 to 1. The preferred formamide is N,N-dimethylformamide. The Vilsmeier reagent is preferably used in excess, serving as a solvent at the same time. However, it is also possible to add an inert solvent such as toluene, chlorobenzene or xylene. The reaction temperature for the Vilsmeier reaction is preferably between 60 and 200 0C.
The Vilsmeier reaction is performed in the presence of a triflate catalyst, more formally known as a trifiuoromethanesulfonate catalyst. Other perfiuoroalkanesulfonate catalyst can also be used. It is preferably a lanthanide(III) or group IV metal trifiuoromethanesulfonate, more preferably the metal cation is copper(II), cerium(IV) or lanthanum(III). The catalyst is preferably present in an amount between 0.1 and 10 wt% based on glycine, more preferably between 0.2 and 8 wt%, most preferably between 0.5 and 5 wt%, based on the weight of glycine.
The final product is a 2-substituted 4-chloro-5-formylimidazole. It is preferably 2-butyl-4-chloro-5-formylimidazole (BCFI), obtained from reacting glycine with methyl pentanimidate, wherein (pentanimidoylamino)acetic acid is the intermediate compound converted in the Vilsmeier reaction. The 2-substituted 4-chloro-5- formylimidazole is typically produced by the process according to the invention with a yield of about 70 - 75 %, based on glycine, and with a purity of more than 99 %, preferably even more than 99.5 % as determined by HPLC. It has also been found that the preparation of a 2-substituted 4-chloro-5- formylimidazole according to US 5,696,272 can start from a simpler and therefore economically attractive nitrile having formula R-C≡N rather than from a commercial- grade imido ester, and in which R has the meaning mentioned above. Furthermore, the reaction of R-C≡N to the imido ester intermediate can be carried out in the remaining established one-pot synthesis, without the requirement of an isolation or purification of the imido ester thus prepared. This makes the additional step even more suitable for industrial scale. Preferably R-C≡N is valeronitrile, leading to the final product 2-butyl- 4-chloro-5-formylimidazole. The invention thus also relates to a process for the preparation of a 2-substituted
4-chloro-5-formylimidazole, wherein said imido ester of formula (II) is prepared by reacting a nitrile having formula R-C≡N, preferably valeronitrile, with methanol in the presence of hydrochloric acid gas, followed by a treatment with ammonia.
This reaction is preferably performed at a temperature between -20 and 10 0C, and HCl gas is blown through the reaction temperature for a time between 5 - 24 hours. It is preferred to add another amount of methanol afterwards, and bring the reaction mixture in a methanolic ammonia solution at a pH between 7 and 11, while the temperature is preferably maintained at 0 - 50 0C. The reaction is completed within 10 hours. The precipitated salts are removed by filtration and washed with an aliphatic alcohol, preferably methanol, and the filtrate could be concentrated in a manner known to those skilled in the art. However, the imido ester is preferably not isolated and instead is further reacted directly with glycine.
It has also been found that a 2-substituted 5-formylimidazole, sometimes also referred to as 2-substituted imidazole-4-carbaldehyde, can conveniently be prepared from the corresponding 4-chloro-5-formylimidazole by applying a hydrodehalogenation step. Yields are observed higher than 50 %, based on glycine, far better than if prepared from the hydroxymethylimidazole as taught in the art. This is surprising, given the fact that this new method of producing 2-substituted 5- formylimidazole involves a more elaborate synthesis route, including an additional step of dechlorination. The method has the advantage that it can be performed as a one-pot synthesis, starting from simple and inexpensive compounds such as valeronitrile and glycine. The invention thus also relates to a process for the production of a 2-substituted 5-formylimidazole of the formula:
Figure imgf000008_0001
in which R is hydrogen, alkyl, alkenyl, cycloalkyl, arylalkyl or aryl, by subjecting the corresponding 2-substituted 4-chloro-5-formylimidazole to hydrodehalogenation in the presence of a noble metal catalyst.
The preferred 2-substituted 5-formylimidazole is 2-butyl 5-formylimidazole, prepared from 2-butyl-4-chloro-5-formylimidazole.
Hydrodehalogenation is performed in the presence of a catalyst comprising a noble metal (including the metallic form as well as the form of a salt, oxide or the like) selected from the group consisting of platinum, palladium and gold. In particular, platinum and palladium are suited for practical use, most preferably palladium. These noble metals may be used in combination with bismuth, cerium, lead, indium or the like as a second component. The noble metal catalyst is used as such or, when necessary, in the form supported on a carrier such as active carbon, silica or alumina. The noble metal catalyst is preferably palladium on carbon, palladium being present in an amount between 5 and 15 wt%, based on the weight of 2-butyl-4-chloro-5-formylimidazole
The hydrodehalogenation is preferably preformed in the presence of an aliphatic alcohol such as methanol, and triethylamine, preferably in an amount of 1 - 20 wt%, more preferably 5 - 15 wt%, based on the total reaction mixture, and a 2 - 10 kg, even more preferably 4 - 5 kg hydrogen pressure, and at a preferred temperature of 0 - 50 0C, more preferably 15 - 30 0C. The noble metal catalyst is preferably present in an amount of 0.1 - 2 wt%, more preferably 0.5 - 1 wt%. In a preferred embodiment the 2-substituted 5-formylimidazole is produced from a 2-substituted 4-chloro-5-formylimidazole that is produced by the process according to the invention, i.e. wherein the Vilsmeier reaction is performed in the presence of a triflate catalyst.
In an even more preferred embodiment the 2-substituted 5-formylimidazole is produced from R-C≡N, wherein R has the meaning cited above, according to the aforementioned process. It is thus possible to produce 2-substituted 5-formylimidazole without any intermediate isolation and purification steps according to an advantageous one-pot synthesis route, thereby reaching yields of more than 50 %, based on glycine, and a purity of more than 98 %, as determined by HPLC.
EXAMPLES
Example 1 - Preparation of methyl pentanimidate from valeronitrile 100 g (1.20 mol) valeronitrile was charged in 58 ml of methanol and cooled to -5 to -10 0C. HCl gas was slowly passed through the solution for 15-18 hrs. Nitrogen pressure of 1.5 to 2.0 kg /cm2 was applied for 14 hrs at 0 - 15 0C, followed by the addition of 55 ml methanol and stirring for another 60 min.
The reaction mass was then transferred to a methanolic ammonia solution (12-15 wt%) and stirred for 3 hrs at 20 - 30 0C, while maintaining the pH at 8 - 9. Precipitated material was then filtered and washed with 25 ml of methanol. The filtrate was concentrated until complete removal of methanol by distillation under reduced pressure
(650-700 mm Hg) at a temperature not exceeding 90 0C. Upon cooling the intermediate
(methyl pentanimidate) was obtained with 95% purity, yield 140 g (1.15 mol; 96 %) as a semi-solid.
Comparative example 1 a. Preparation of 2-butyl-4-hvdroxymethylimidazole (BHI)
140 g (1.15 mol) methyl pentanimidate prepared according to the method of example 1, 95 % purity and 84 g (0.93 mol) 1,3-dihydroxyacetone were charged in 47 ml of isopropyl alcohol and cooled to 0 - 5 0C. Ammonia gas was passed through at a pressure of 13 - 16 kg/cm2 at a temperature of 65 - 70 0C while stirring for 6 hrs. The reaction mixture was cooled to room temperature and the ammonia pressure was released. The reaction mixture was then subsequently heated to 55 - 60 0C, transferred to 350 ml of deionised water, stirred for 30 min, and cooled to 0 - 5 0C. The cold mixture was stirred for another 5 hrs at 0 - 5 0C, filtered and washed with 25 ml of deionised water. Crude material was recrystallised by dissolution into 100 ml of acetonitrile at 65 - 70 0C. The clear solution was then cooled to 0 - 5 0C and stirred for another 2 hrs. Finally, the solid material was filtered off, washed with 12.5 ml of acetonitrile and dried under vacuum at 30 - 40 0C for 6 - 8 hrs. The yield of 2-butyl-4- hydroxymethylimidazole obtained was 87 g (0.55 mol ; 48 %) with a purity of 97% by HPLC.
b. Preparation of 2-butyl-5-formylimidazole from BHI
920 ml of 2.5% sodium hydroxide solution, 6.8 g of 5% platinum on carbon, 1.05 g bismuth sulfate and 85 g (0.54 mol, 97% purity by HPLC) of 2-butyl-4- hydroxymethylimidazole were mixed at ambient temperature and then heated to 53 - 55 0C. 50% hydrogen peroxide solution (46 g) was added in 2 - 3 hrs at 58 - 62 0C. While stirring for another 90 min oxygen was passed through the solution to further increase the conversion to at least 85%. The conversion was monitored by in-process analysis.
When the conversion was complete, the reaction mixture was cooled to 50 - 55 0C, followed by filtration to remove the platinum on carbon. The filtered catalyst was washed with 25 ml of deionised water. The remaining reaction mixture was cooled to 10 - 15 0C and the pH adjusted to 7.5 - 8.0 using 50% sulfuric acid, and stirred for another 3 hrs before filtering and washing with 2 x 50 ml of chilled deionised water (10 0C).
The crude material was purified by recrystallisation from dichloromethane and hexane to give a yield of 51.5 g (0.33 mol, 61% ) of 2-butyl-5-formylimidazole with 98% purity.
Example 2 - Preparation of BCFI from methyl pentanimidate using a triflate catalyst 50 g (0.666 mol) of glycine was added to freshly prepared methanolic sodium hydroxide solution (sodium hydroxide 26.64 g (0.666 mol) in 250 ml of methanol) at O0C and stirred for another 15 min. 80 g (0.70 mol) of the methyl pentanimidate prepared according to example 1 was added over a period of 10 - 15 min to the above suspension at 0 - 5 0C and stirring was continued for 16 hrs at room temperature. The solvent was then distilled under vacuum below 5O0C. 500 ml of toluene was added to the above reaction mass, followed by 0.25 g of Copper(II) trifluoromethanesulfonate. Then 320 g (2.08 mol) of phosphorous oxychloride was added to this reaction mixture in 60 min, followed by 150 g (2.05 mol) N,N-dimethylformamide in 2 hrs. The reaction mixture was heated to 100 0C and stirred for 2 hrs, then cooled to 30 0C and quenched in 260 ml of cooled deionised water (temperature below 25 0C). 30 g of filter aid (hi-flow) was added and the pH adjusted to 1.2 using 440 ml of 30% aqueous sodium hydroxide solution.
It was then filtered and washed with 100 ml of toluene, and the layers were separated. The toluene layer was washed twice with deionised water (400 ml each time). 8 g of activated carbon was added to the toluene and the layer was stirred for 30 min at 30 - 35 0C, followed by filtration and washing with 100 ml of toluene. All toluene layers were combined and concentrated to 50 vol% under vacuum below 55 0C. The concentrated toluene solution was then cooled to 0 - 5 0C and stirred for 2 hrs, followed by filtration of the precipitated product and washing with 25 ml of chilled toluene, to yield a wet material, which upon drying at 50 - 55 0C to constant weight resulted in 89 g (0.47 mol) of crystalline 2-butyl-4-chloro-5-formylimidazole (yield 71 %). The analysis of this product by HPLC gave a purity of 99.8%, confirmed by IR. Melting range 95 - 99 0C.
Comparative example 2 - Preparation of BCFI without triflate catalyst
The procedure reported in example 2 was exactly repeated, with the only difference that phosphorous oxychloride was now added in the absence of Copper(II) trifluoromethanesulfonate. All other steps, including reaction times and temperatures, were in accordance with those mentioned in example 2. It resulted in a wet material, which upon drying at 50-55 0C to constant weight resulted in 82.7 g (0.4431 mol) of crystalline 2-butyl-4-chloro-5-formylimidazole (yield 66.4%). The analysis of this product by HPLC showed a purity of 92.5%, based on glycine. The yield and purity were comparable to those mentioned in example 4 of US 5,696,272 (62.0 % yield and 85 % HPLC purity), using a corresponding synthesis route and the same starting materials.
In order to arrive at the purity levels reported in example 2 (preparation of BCFI in the presence of a triflate catalyst), extensive purification, including a charcoal treatment, was required, accompanied by a drop in yield to about 50 %. Example 3 - Preparation of BFI from BCFI
In an autoclave 50 g (0.27 mol) of 2-butyl-4-chloro-5-formylimidazole was brought in 500 ml of methanol and 32 g of triethylamine was added hereto, followed by 2.5 g of 10% palladium on carbon. The hydrogen pressure in the autoclave was kept at 4 - 5 kg /cm2 at 20 - 25 0C for 8 - 10 hrs, while monitoring the reaction by thin layer chromatography.
At the end of the reaction, the mixture was taken from the autoclave and the solvent was removed under reduced pressure below 500C. 250 ml of deionised water was added to the dried mixture and it was cooled to 25-300C. The pH was adjusted to 1.2 using diluted hydrochloric acid. The aqueous layer was then washed with 50 ml of dichloromethane to remove traces of the starting material. The pH was then readjusted to 6.8 - 7.5 using a sodium carbonate solution, and the aqueous layer was extracted with 3 x 150 ml of dichloromethane. Afterwards, the dichloromethane was dried with sodium sulfate for 30 min and then filtered to remove the sodium sulfate. This was followed by evaporation to dryness. 250 ml of hexane was added hereto at a temperature of 45 0C, and then cooled to 10 - 15 0C for 30 min, to obtain 2-butyl-5- formy limidazo Ie .
The product was isolated by filtration followed by washing with 100 ml of chilled hexane (10 0C) and dried at 55 - 60 0C for 6 hrs. The yield of the dried material was 30 - 33 g (0.20 - 0.22 mol; 74 - 81 %). The analysis of this product by HPLC gave 99.1% purity, confirmed by IR.
Example 4 - Preparation of BFI from valeronitrile 58 g (1.2 mol) of valeronitrile was charged in 34 ml of methanol and cooled to -5 to -
10 0C. Hydrochloric acid gas was slowly passed through for 15 - 18 hrs. The nitrogen pressure was kept at 1.5 to 2.0 kg/cm2 for 14 hrs at 0 - 15 0C, followed by the addition of 32 ml of methanol while stirring for 60 min.
The reaction mass was transferred to a methanolic ammonia solution (12 - 15 wt% and stirred for 3 hrs at 20 - 30 0C, while keeping the pH at 8.0 - 9.0. Precipitated material was filtered off and washed with 15 ml of methanol. The filtrate was concentrated by distillation under reduced pressure (650 - 700 mm Hg) at a temperature not exceeding 900C, followed by cooling to give pentanimidate. 50 g (0.666 mol) of glycine was added to a freshly prepared methanolic sodium hydroxide solution (sodium hydroxide 26.64 g (0.666 mol) in 250 ml of methanol) at
O0C and stirred for 15 min. The above prepared, 80 g pentanimidate was added at 0 - 5
0C in 10 - 15 min and the mixture was stirred for another 16 hrs at room temperature. The solvent was distilled under vacuum while keeping the temperature below 5O0C.
500 ml of toluene was added to the above reaction mass, followed by 0.25 g of Copper(II) trifluoromethanesulfonate. Then 320 g (2.08 mol) of phosphorous oxychloride and 150 g (2.05 mol) N,N-dimethylformamide were added successively in 60 minutes and 2 hours, respectively. The reaction mixture was heated to 100 0C and stirred for another 2 hrs, then cooled to 30 0C and quenched in 260 ml of cooled water having a temperature below 250C. 30 g of filter aid (hi-flow) was added and the pH adjusted to 1.2 with 440 ml of 30 % aqueous sodium hydroxide solution.
It was then filtered and washed with 100 ml of toluene, and the layers were separated. The toluene layer was washed twice with deionised water (400 ml each time), and 8 g of activated carbon was added to the toluene and stirred for 30 min at 30 - 35 0C, followed by filtration and washing with 100 ml of toluene. All toluene layers were combined and concentrated to dryness under vacuum below 55 0C. The concentrated mass was cooled to 30 0C. The weight of the residue was 96 g.
500 ml of methanol and 60 g of triethylamine was added hereto, followed by 4.5 g of 10% palladium on carbon in the autoclave. The hydrogen pressure was kept at 4 - 5 kg/cm2 at 20 - 25 0C for 8 - 10 hrs, while monitoring the reaction by thin layer chromatography.
At the end of the reaction, the mixture was unloaded from the autoclave. The solvent was removed under reduced pressure, thereby keeping the temperature below 50 0C. 250 ml of deionised water was added and it was cooled to 25 - 30 0C. The pH was adjusted to 1.2 with diluted hydrochloric acid and the aqueous layer was extracted with 60 ml of dichloromethane to remove traces of the starting material. The pH was then readjusted to 6.8 - 7.5 using sodium carbonate solution, and the aqueous layer was extracted with 3 x 160 ml of dichloromethane. The dichloromethane solution was dried with sodium sulfate for 30 min and the sodium sulfate removed by filtering. The filtrate was evaporated to dryness, 300 ml of hexane was added at 45 0C, and the mixture was cooled to 10 - 15 0C and maintained at that temperature for another 30 min, to obtain 2- butyl-5 - formy limidazo Ie . The product was isolated by filtration followed by washing with 150 ml of chilled hexane (10 0C) and dried at 55 - 60 0C for 6 hrs, with a yield of 58 g. Analysis of the product by HPLC showed 99.0 % purity. The yield was about 55 % on the basis of valeronitrile.

Claims

1. A process for the preparation of a 2-substituted 4-chloro-5-formylimidazole of the formula:
Figure imgf000015_0001
in which R is hydrogen, alkyl, alkenyl, cycloalkyl, arylalkyl or aryl, wherein glycine is reacted with an imido ester of the formula:
Figure imgf000015_0002
in which R has the meaning recited above, and Ri is alkyl, to give a compound of the formula:
Figure imgf000015_0003
which is then subjected to a Vilsmeier reaction using a chlorinating agent and a formamide of the formula:
Figure imgf000015_0004
in which R2 and R3 are identical or different and each is a (C1-C4) alkyl, characterized in that said Vilsmeier reaction is performed in the presence of a triflate catalyst.
2. The process according to claim 1, wherein said imido ester II is prepared by reacting a nitrile having formula R-C≡N with methanol in the presence of hydrochloric acid gas, followed by a treatment with ammonia.
3. The process according to claim 2, wherein said imido ester II is not isolated and instead is further reacted directly with glycine.
4. The process according to any one of the preceding claims, wherein said 2- substituted 4-chloro-5-formylimidazole is 2-butyl-4-chloro-5-formylimidazole (R = butyl).
5. The process according to any one of the preceding claims, wherein said 2- substituted 4-chloro-5-formylimidazole is subjected to hydrodehalogenation in the presence of a noble metal catalyst, to obtain a 2-substituted 5-formylimidazole of the formula:
Figure imgf000016_0001
in which R has the meaning as defined in claim 1.
6. A process for the preparation of a 2-substituted 5-formylimidazole V, in which R has the meaning as defined in claim 1, by subjecting a 2-substituted 4-chloro-5- formylimidazole to hydrodehalogenation in the presence of a noble metal catalyst.
7. The process according to claim 5 or 6, wherein said noble metal catalyst is palladium on carbon.
8. The process according to any one of claims 5 - 7, wherein said 2-substituted 5- formylimidazole is 2-butyl-5-formylimidazole.
PCT/NL2006/050077 2005-04-15 2006-04-07 Preparation of 2-substituted 4-chl0r0-5-f0rmylimidaz0les by vilsmeier reaction of the condensation product of glycine and an imido ester with a formamide in the presence of a triflate (trifluormethanξsulphonate) catalyst Ceased WO2006110037A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE602006017675T DE602006017675D1 (en) 2005-04-15 2006-04-07 PREPARATION OF 2-SUBSTITUTED 4-CHLORO-5-FORMYLIMIDAZOLENES BY VILSMEIER RESPONSE OF THE CONDENSATION PRODUCT OF GLYCIN AND AN IMIDOESTER WITH A FORMAMID IN THE PRESENCE OF A TRIFLATED (TRIFLUOROMETHANE SULFONATE) CATALYST
US11/911,659 US20080200690A1 (en) 2005-04-15 2006-04-07 Preparation of 2-Substituted 4-Chloro-5-Formylimidazole and 5-Formylimidazole
EP06733056A EP1871745B1 (en) 2005-04-15 2006-04-07 Preparation of 2-substituted 4-chloro-5-formylimidazoles by vilsmeier reaction of the condensation product of glycine and an imido ester with a formamide in the presence of a triflate (trifluormethanesulphonate) catalyst
JP2008506390A JP2008535911A (en) 2005-04-15 2006-04-07 Preparation of 2-substituted 4-chloro-5-formylimidazole and 5-formylimidazole
AT06733056T ATE485278T1 (en) 2005-04-15 2006-04-07 PREPARATION OF 2-SUBSTITUTED 4-CHLORINE-5-FORMYLIMIDAZOLES BY VILSMEIER REACTION OF THE CONDENSATION PRODUCT OF GLYCINE AND AN IMIDOESTER WITH A FORMAMIDE IN THE PRESENCE OF A TRIFLATE (TRIFLUOROMETHANE SULFONATE) CATALYST

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67147105P 2005-04-15 2005-04-15
EP05103014.6 2005-04-15
EP05103014 2005-04-15
US60/671,471 2005-04-15

Publications (2)

Publication Number Publication Date
WO2006110037A2 true WO2006110037A2 (en) 2006-10-19
WO2006110037A3 WO2006110037A3 (en) 2007-04-05

Family

ID=34939316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2006/050077 Ceased WO2006110037A2 (en) 2005-04-15 2006-04-07 Preparation of 2-substituted 4-chl0r0-5-f0rmylimidaz0les by vilsmeier reaction of the condensation product of glycine and an imido ester with a formamide in the presence of a triflate (trifluormethanξsulphonate) catalyst

Country Status (6)

Country Link
US (1) US20080200690A1 (en)
EP (1) EP1871745B1 (en)
JP (1) JP2008535911A (en)
AT (1) ATE485278T1 (en)
DE (1) DE602006017675D1 (en)
WO (1) WO2006110037A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696272A (en) 1996-01-05 1997-12-09 Lonza Ltd. Process for the production of 2-substituted 5-chloroimidazole-4-carbaldehydes
US6040457A (en) 1997-11-14 2000-03-21 Lonza Ag Process for the preparation of formylimidazoles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
RU2103262C1 (en) * 1992-07-16 1998-01-27 Лонца АГ Гампель/Валлис Method for production of 2-substituted 5-chloroimidazole-4-carbaldehydes
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
US5484939A (en) * 1993-03-12 1996-01-16 Lonza Ltd. 2-substituted 5-chlorimidazoles
US5442075A (en) * 1993-03-12 1995-08-15 Lonza Ltd. Process for the production of 2-substituted 5-chlorimidazole-4-carbaldehydes
CA2135541C (en) * 1993-11-15 2006-01-10 Gareth Griffiths Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696272A (en) 1996-01-05 1997-12-09 Lonza Ltd. Process for the production of 2-substituted 5-chloroimidazole-4-carbaldehydes
US6040457A (en) 1997-11-14 2000-03-21 Lonza Ag Process for the preparation of formylimidazoles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. DAVOOD ET AL.: "Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4(5)-chloro-2-methyl-5(4)-imidazolyl substituent", BOLLETTINO CHIMICO FARMACEUTICO, vol. 140, no. 6, 2001, pages 381 - 386
P. AMBALAVANAN ET AL.: "Crystal structures of two imidazole derivatives", MOL. CRYST. LIQ. CRYST., vol. 393, 2003, pages 75 - 82

Also Published As

Publication number Publication date
EP1871745B1 (en) 2010-10-20
US20080200690A1 (en) 2008-08-21
WO2006110037A3 (en) 2007-04-05
ATE485278T1 (en) 2010-11-15
JP2008535911A (en) 2008-09-04
DE602006017675D1 (en) 2010-12-02
EP1871745A2 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
EP0260817B1 (en) Quinazolinediones and pyridopyrimidinediones
US9840490B2 (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
US20230104954A1 (en) Process for preparing 5-fluoro-4-imino-3-methyl-1-(toluene-4-sulfonyl)-3,4-dihydro-1h-pyrimidin-2-one
KR102406358B1 (en) Process for manufacturing pyrimidine sulfamide derivatives
JP2008516005A (en) Improved preparation of letrozole
EP4313954B1 (en) Preparation of 2-chloro-4-fluoro-5-nitrobenzoic acid
CA2091333C (en) Process for the production of guanidine derivatives
EP1871745B1 (en) Preparation of 2-substituted 4-chloro-5-formylimidazoles by vilsmeier reaction of the condensation product of glycine and an imido ester with a formamide in the presence of a triflate (trifluormethanesulphonate) catalyst
IE891996L (en) Process for the preparation of¹2,6-dichlorodiphenylamino-acetic acid derivatives
IE59937B1 (en) Quinazolinediones and pyridopyrimidinediones
JP3269192B2 (en) Method for producing 2-halogen-4,6-dialkoxy-pyrimidine
US10875831B1 (en) Process for preparing 1,4-dihydro-4-oxoquinoline-2-carboxylates and 4-aminoquinoline compounds therefrom
JP4852528B2 (en) Method for producing oxcarbazepine
WO2009017239A2 (en) Process for producing toluidine compound
CN101163680A (en) Preparation of 2-substituted 4-chloro-5-formyl imidazoles by Viersmeyer reaction of condensation products of glycine and imidate with formamide in the presence of trifluoromethanesulfonic acid catalyst
JP3716434B2 (en) 2-substituted-5-chloroimidazole
EP0968994A1 (en) Substituted trifluorobenzoic acids, esters thereof, and process for producing the same
JP3573249B2 (en) 2,3,4-trifluoro-5-iodobenzoic acid, esters thereof and process for producing the same
JP2007528385A6 (en) Method for producing oxcarbazepine
JP2003506312A (en) Meta-nitrophenol derivative and method for producing the same
JP2852023B2 (en) Method for producing 2-fluorocyclopropylamine sulfonate and its chemical compound 2-fluorocyclopropyl isocyanate
JP2002517481A (en) New manufacturing method
EP1963309B1 (en) Method for producing metal salts of losartan
KR19990007971A (en) Process for preparing substituted aryluracil
EP1877402A1 (en) A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680012405.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006733056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7890/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008506390

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11911659

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06733056

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006733056

Country of ref document: EP